Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 81

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 81
---
 October 2024 Common Warrant Shares under the Securities Act is not effective or available, the holder may, in its sole discretion, elect to exercise the October 2024 Common Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the October 2024 Common Warrants.

The exercise price of the October 2024 Common Warrants, and the number of October 2024 Common Warrant Shares, is subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the October 2024 Common Warrants. In addition, the October 2024 Common Warrants provide that we may also at any time during the term of the October 2024 Common Warrants, subject to the prior written consent of the holder, voluntarily reduce the then current exercise price to any amount and for any period of time, subject to the rules and regulations of Nasdaq.

| 42 |

A holder will not have the right to exercise any portion of the October 2024 Common Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

In the event of a Fundamental Transaction (as such term is defined in the October 2024 Common Warrants), then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may exercise and will assume all of our obligations under the October 2024 Common Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the October 2024 Common Warrants following such Fundamental Transaction. In addition, the successor entity, at the request of holders of October 2024 Common Warrants, will be obligated to purchase any unexercised portion of the October 2024 Common